Brief: Oncolytics Biotech Inc Says As Of September 30, 2021, Co Reported $48.1 Mln In Cash And Cash Equivalents

Oncolytics Biotech

05/11/2021 12:30

Nov 5 (Reuters) - Oncolytics Biotech Inc  ONC.TO :
    * ONCOLYTICS BIOTECH INC - AS OF SEPTEMBER 30, 2021, COMPANY
REPORTED $48.1 MILLION IN CASH AND CASH EQUIVALENTS
    * ONCOLYTICS BIOTECH INC - RESEARCH AND DEVELOPMENT EXPENSE
FOR Q3
OF 2021 WAS $3.3 MILLION, COMPARED TO $3.9 MILLION
    * ONCOLYTICS BIOTECH INC - QTRLY BASIC AND DILUTED LOSS PER
SHARE
WAS $0.09
    * ONCOLYTICS BIOTECH INC - SEES COMPLETION OF ENROLLMENT IN
PHASE
2 BRACELET-1 METASTATIC BREAST CANCER STUDY BY Q4 2021 OR Q1
2022
    * ONCOLYTICS BIOTECH INC - SEES INTERIM SAFETY UPDATE FROM
PHASE 2
IRENE STUDY IN TRIPLE-NEGATIVE BREAST CANCER BY Q4 2021

Source text for Eikon:  ID:nPnMqnNMa 
Further company coverage:  ONC.TO 

 ((Reuters.Briefs@thomsonreuters.com;))